Juvenile idiopathic arthritis (JIA) is a group of arthritis diseases of unknown cause occurring in children younger than 16 years. These diseases are sometimes called juvenile chronic arthritis. The name was changed from juvenile rheumatoid arthritis to avoid confusion with adult rheumatoid arthritis. In JIA, the immune system attacks synovium (tissue lining the joint). The synovium becomes inflamed, causing swelling, pain, and stiffness. This process can spread to surrounding tissues, damaging cartilage and bone. There are currently about 300 000 children with JIA in the United States. The April 7, 2010, issue of JAMA includes an article about JIA.
Grahic Jump Location
Children with any type of JIA can have morning stiffness; pain, swelling, and tenderness in joints; limping; fever; rash; weight loss; fatigue or irritability; and eye redness, pain, or blurred vision. Chronic eye inflammation occurs in 10% to 20% of all patients; of these, 30% to 40% have a severe loss of vision.
Treatment responses may vary. The goals are to relieve pain, reduce swelling, increase joint mobility and strength, and prevent joint damage. Exercise, physical therapy, and occupational therapy reduce pain, maintain muscle tone, improve function, and prevent permanent disability. Although new therapeutic options have been introduced, it is still not easy to predict the treatment response in children. Medications can include
nonsteroidal anti-inflammatory drugs (NSAIDs), which provide pain relief and reduce swelling but do not affect the course of JIA.
corticosteroids, which can be given orally or as an injection.
disease-modifying antirheumatic drugs (DMARDs), which suppress the body's immune system.
biological-modifying agents, which are used to treat children with severe arthritis that is not responsive to other medications.
There are no specific tests for JIA. Patients should undergo a complete physical examination. X-rays and lab tests can help determine the kind of arthritis the patient has and rule out other problems.
If untreated, JIA complications can include lost or decreased vision, permanent joint damage, chronic arthritis and loss of function, interference with bones and growth, and inflammation of the membranes surrounding the heart or lungs.
Many children outgrow the disease by adulthood, but others continue to need treatment as adults. To date, there are no means to determine the prognosis or long-term need for medication in individual patients.
American College of Rheumatologyhttp://www.rheumatology.org
Arthritis Foundationhttp://www.arthritis.org
To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA's Web site at http://www.jama.com. Many are available in English and Spanish. A Patient Page on JIA was published in the October 5, 2005, issue.
Sources: American College of Rheumatology, Arthritis Foundation
The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.
TOPIC: ARTHRITIS
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.